News & Updates
Filter by Specialty:
Nintedanib falls short in bladder cancer trial
In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).
Nintedanib falls short in bladder cancer trial
21 Jun 2022
Ceritinib shows therapeutic potential in ALK-positive nonsmall cell lung cancer
The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.
Ceritinib shows therapeutic potential in ALK-positive nonsmall cell lung cancer
21 Jun 2022
Pandemic-caused treatment delays for cancer may aggravate psychological distress
Cancer patients who experience treatment delays due to the COVID-19 pandemic restrictions may be vulnerable to psychological distress, reports a recent China study. Effective communication from doctors and other cancer care professionals may help mitigate this effect.
Pandemic-caused treatment delays for cancer may aggravate psychological distress
18 Jun 2022
Dostarlimab a miraculous cure for mismatch repair-deficient, locally advanced rectal cancer?
Use of dostarlimab, a single-agent programmed death 1 (PD-1) monoclonal antibody, appears to have successfully cured mismatch repair-deficient, locally advanced rectal cancer, reports a recent study.
